Teva discontinues mid-stage neurodegenerative disorder study

Teva Pharmaceuticals said on Monday it was discontinuing its mid-stage neurodegenerative disorder study due to a low probability of meeting its main goal if continued.

Read the full story at Reuters AI ↗

Timeline · 1 report

2026-11-02 15:45 · Reuters AI
Teva to discontinue mid-stage neurodegenerative disorder study

More stories

OpenAI launches Grid Protectors Program to curb compute campuses' power demand — OpenAI News
Anthropic reports nearly $17 billion quarterly revenue ahead of IPO — CNBC Technology
Musk says Grok Bot usage limits cut due to 'unsustainably high' costs — Forbes AI
Anthropic updates Claude Code to block recreation of existing video games — Engadget
Musk mocks Altman's RAM comments as OpenAI weighs renaming data centres — The Verge AI
Anthropic's amended IPO filing shows $17bn revenue, $3.5bn share sale to Japan investors — Reuters AI
Malicious Claude Code extension pulled from Cursor marketplace after SSH backdoor attempt — Microsoft Research Blog
DeepSeek open-sources dsh-superagent, a proactive autonomous coding agent prototype — Bloomberg AI

Get the daily brief of stories like this at 6:30 every morning →